Amgen "outperform"

11.05.07 - Robert W. Baird

NEW YORK, May 11 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on Amgen Inc (AMGN). The target price is set to $80.

In a research note published this morning, the analysts mention that the recent ODAC panel review of the company?s ESAs was disappointing. The analysts add, however, that commercially viable additional restrictions on the use of ESAs would require further clinical data and clinical trials. The additional requirement of Aranesp label changes is unlikely in the near term, Robert W Baird says.